EVAHF Low-Float Biotech w/ Huge Upside Potential

EGF Theramed Health Corp. (EVAHF)
Canada: CSE:TMED
Germany: FWB:AUHP
Alert Price: $0.3757
Float: 2.9M
We have been on quite the hot streak as of late.
Our last three winning trade ideas have delivered gains of +97%, +30%, and +105% respectively.
You'll be happy to know that we have just come across another exciting trade idea with monster gain potential.
Please turn your immediate attention to EVAHF (EGF Theramed Health Corp.).
This is one of the most attractive opportunities we've seen in quite some time for several reasons.
The Company:

Is Listed On Major Exchanges In Three Different Countries (U.S., Canada, and Germany)
Trades On The OTCQB, Which Means That It Is Current In Its Reporting, Undergoes Annual Verification & Certification, And Is Not In Bankruptcy
Has A Razor Thin Float
Recently Completed A Big-Time Acquisition
Is Now Operating In A Mental Health Market That Many Experts Believe Is Going To Explode
With its small float, and commitment to growth, EVAHF is cut from the same cloth as our most recent mega-winners.

The Company recently closed a joint venture transaction with Pharmadelic Labs Corp. in which they acquired a 30% interest in the Biosynthesis company.

With this recent acquisition EVAHF is now on the cutting edge when it comes to the treatment of mental health.

EVAHF has begun to research psilocybin and psychedelic extraction and processing which it hopes to use in its Las Vegas extraction lab. Psilocybin microdosing is known to reduce stress, anxiety and pain without many of the side effects associated with traditional pharmacology products that have been prescribed for the same issues.

This comes at a time when a research study suggests that as many as 150,000 additional people could die from mental health-related outcomes.

This could easily be our next trade idea to gain in price, so we suggest you start your research now, and add EVAHF to the top of your watchlist immediately.

About EGF Theramed Health Corp. (OTCQB:EVAHF CSE:MED FWB:AUHP)

EGF Theramed Health Corp. has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations.

Through the Company’s recent acquisition of a 30% equity interest in Pharmadelic Labs Corp. it has begun to research psilocybin and psychedelic biosynthesis and processing for its Las Vegas extraction lab. Psilocybin microdosing has been shown to reduce stress, anxiety and pain without many of the side effects associated with traditional pharmacology products that have been prescribed for the same issues.

About Pharmadelic Labs Corp.

Pharmadelic Labs is genetically designing proprietary processes to help create pharmaceutical grade psilocybin-derived ingredients in a synthetic lab environment. Genetic engineering and biosynthesis expedite a process that creates unique modified psilocybin compounds and precursors in a far more efficient and cost effective manner than traditional methods

Pharmadelic Labs aims to develop a portfolio of intellectual property around biosynthesis pathways for creating compounds. This has great potential for application in many industries including the pharmaceuticals industry.

The company's patent portfolio will develop as follows:

File for provisional patent applications
Continue to update patents as technology develops
Strengthen existing patents with further applications around biosynthesis pathways as results are known

Pharmadelic Labs' biosynthesis process is clean and economical, and much quicker than cultivating mushrooms by themselves – approximately 3 days rather than up to 10 weeks!

It also ensures consistent levels of PSI and is safe due to yeast’s status as Generally Recognized as Safe (GRAS).

The company will also be providing an effective alternative to chemical synthesis. Chemical synthesis of PSI costs upwards of $7K per gram, which is far more expensive than the company's methods.

Very few companies will get an FDA drug approved, maybe a handful at best, hundreds of them will attempt to do so as the race has ultimately begun for PSY billions as the sector opens up, but everyone will need an edge over their competition.

This edge is not in the drug itself or the molecule, or the compound, but may be in the process and the way the compound is mass produced in a lab environment.

Here Is How The Biosynthesis Of PSI Works:

Step 1 Order synthetic DNA from hal*luc*ino*genic mushrooms
Step 2 Install DNA into genome of industrial brewing yeast
Step 3 Cultivate yeast on a large scale
Step 4 Extract PSI
Step 5 Create pharmaceutical product
PSI May Be The Next Breakthrough Therapy For Depression and Other Mental Issues

Ma*gic mushrooms are the safest “recreational” drug to take and those who take them are the most sensible and well prepared, according to the 2017 Global Drug Survey. Out of almost 10,000 people who took them, only 0.2% needed emergency medical treatment.

Ongoing clinical trials are discovering the uses of PSI in the treatment of addiction and other mental health problems.

The "Green Wave" rush when it emerged sent MJ related stocks soaring as the plant promises to offer a long list of benefits for various ailments.

More and more studies are examining the properties of PSI, and the enormous effects that it can have on the huge global problem of treating mental health.Check out some of the studies around PSI:

A single dose of the PSY ingredient in "ma*gic mushrooms" may bring long-lasting relief to cancer patients who suffer anxiety and depression, a new, small study suggests. (SOURCE)
Doctors Are Turning to PSYs to Treat Depression and Addiction (SOURCE)
A Radical Approach to Beating Addiction (SOURCE)
Doctors Are Giving Alzheimer's Patients L-S-D (SOURCE)
Researchers from the University of South Florida discover that PSI can also bind itself to receptors that stimulate healing. (SOURCE)
Mental Health Market Creates Tremendous Revenue Potential

According to the Centers for Disease Control, suicide was the 10th leading cause of death in the US in 2017.

Healthypeople.gov has found that in any given year, over 18% of US adults suffer from mental illness.

Forbes has reported that mental illness costs the U.S. economy nearly $200B a year.

According to Brands Essence Research, the global antidepressant drugs market was estimated to be over $13.5Bn in 2018 and is predicted to rise to nearly $16B by 2025.

36% of Americans told an American Psychiatric Association poll that the pandemic has had a serious impact on their mental health, and according to a PiplSay poll, 31% of Americans say they’re sleeping less because of c-virus-related anxiety.

As people self-quarantine, remote therapy services like Talkspace and Brightside have seen an increase in demand. In fact, Talkspace told Bloomberg at the beginning of April that it experienced a 65% increase in customers since mid February and Brightside has seen a 50% increase in new users since the start of the year.

EVAHF Is Positioning Itself To Help Solve A $280 Billion Per Year Problem In The U.S.

Mental health is one of the biggest unsolved health problems in the world. It is pervasive; it is estimated that up to one quarter of Americans can suffer a mental disorder in any given year. This has a striking economic impact; treating mental health is estimated to cost the US more than $280 billion per year - before economic losses due to time off work is calculated. The global antidepressants market is estimated to grow to over $22 billion by 2025 - this represents a huge potential market for psychedelic drugs to enter.

Current treatments such as opioids have potentially harmful side effects such as addictiveness, but psychedelic drugs like psilocybin may avoid these downsides of addiction. An article published by Johns Hopkins University in 2018 recommended that the government downgrade psilocybin's classification to Schedule IV: a drug with "low potential for abuse and low risk of dependence". It has shown promising results in treating depression, as well as in palliative care.

As the government and more pharmaceutical companies recognize the medical treatment potential of psychedelic substances, it is important that access to compounds like psilocybin is made easier. Pharmadelic Labs is aiming to achieve this by creating biosynthesis pathways for psilocybin.

FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Forms of Depression

The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder (MDD).

For the second time in a year, the U.S. Food and Drug Administration (FDA) has designated psilocybin therapy — currently being tested in clinical trials — as "breakthrough therapy," an action that is meant to accelerate the typically sluggish process of drug development and review. It is typically requested by a drug company and granted only when preliminary evidence suggests the drug may be an enormous improvement over already available therapy, according to the FDA.

Last year, the FDA granted "breakthrough therapy" status to psilocybin therapy in the still-ongoing clinical trials run by the company Compass Pathways, which are looking into psilocybin's potential to treat severe treatment-resistant depression, or depression in patients who have not improved after undergoing two different antidepressant treatments, according to New Atlas.

Recent News

EGF Theramed Health Announces Leased Facilities for Pharmadelic Labs

Two weeks ago, the Company announced that its joint venture partner, Pharmadelic Labs Corp. ("Pharmadelic Labs"), in which the Company holds a 30% equity interest, has secured additional lab facility space in order to expand its research and development of proprietary processes to help create pharmaceutical grade psilocybin-derived ingredients in a synthetic lab environment.

Pharmadelic Labs has a leased space at a lab facility in Burnaby, British Columbia at a cost of $3,000 per month expiring May 1, 2021 and has begun plans for some minor retrofitting in advance of ordering/receiving DNA and certain lab equipment. Operations in Burnaby will focus on research on precursor molecules such as 4-hydroxytryptamine, norbaeocystin, baeocystin, and norpsilocin, which are not on the controlled substances list in Canada. There are also derivatives of 4-hydroxytryptamine and norpsilocin that will be pursued during this phase of research and development.

The ongoing research will focus on the genetic engineering of yeast for biosynthesis of these target molecules. Testing will be conducted using HPLC with mass spec (LC/MS) for metabolite analysis, while DNA sequencing will be used for confirmation of genetic modifications and genomic installations. Once small-scale fermentations are ready for trial there will be investigations into optimizing the metabolic pathway(s) of interest.

Pharmadelic Labs has also entered into a lease for a lab facility in Victoria, British Columbia at a cost of $5,000 per month effective August 1, 2020. The lease has an initial term of six months and is renewable at the Company's option and the satisfaction of certain conditions. The parties are currently working together reviewing lab equipment requirements in order to acquire the necessary equipment for this location. Once the lab is set-up, it is expected that Pharmadelic Labs will move all Canadian operations to Victoria and it will become their headquarters for ongoing research and development activities with precursor molecules, as well as controlled-substances, subject to drug research exemptions from the appropriate regulatory institutions.

Under the joint venture agreement, the Company has advanced funds to Pharmadelic Labs to allow it to move forward with patent filings focusing on biosynthesis of derivatives of tryptamine/psilocybin and several precursors there-in. Pharmadelic Labs is continuing to examine different DNA samples from various psilocybin producing mushrooms to determine the optimal one to use in the biosynthesis process with yeast.

Market Outlook

Studies Have Shown a Possible Increase In Drug Deaths as High as 150K

There is a research model going around that suggests as many as 150,000 additional people could die from mental health-related outcomes.

The federal mental health czar is calling for more money to expand services to help people suffering amid the social isolation, as a new study estimates related deaths from alcohol, drug overdose and suicide could reach 150,000.

"We see very troubling signs across the nation," said Dr. Elinore McCance-Katz, assistant secretary at Department of Health and Human Services and head of the Substance Abuse and Mental Health Administration. "There's more substance abuse, more overdoses, more domestic violence and neglect and abuse of children."

McCance-Katz said the agency wants more money for services to address an anticipated surge in need for mental health and addiction treatment, which was already in short supply. She cited HHS' own substance abuse and mental health research and a February report in the British journal The Lancet on the psychological effects of quarantine

The Lancet study said the effects can include post-traumatic stress disorder and suicide and are "wide-ranging, substantial, and can be long lasting." That's especially true if there isn't a clear end in sight, like now, said McCance-Katz.

The new study, released Friday by the Well Being Trust and the American Academy of Family Physicians, factored in isolation and uncertainty when it calculated the expected deaths from suicide, alcohol and drugs, based on nine unemployment scenarios.

The likely toll from these "deaths of despair" was the loss of an additional 75,000 lives, the study found. Death estimates ranged from 27,644 if the economy recovers quickly, to 154,037 if recovery is slow.

Based on the data we've read, it appears that a sharp increase in spending toward mental health is inevitable.

This is certainly not the most uplifting news, but we do see it as a bullish catalyst for EVAHF.

Technical Analysis

EVAHF Has A Razor Thin Float And Tremendous Upside Potential

Potential Bullish Reversal In The Making

We did our very own technical analysis, and see the potential for a major move from here.

Bullish Indicators

Beautiful Bottom And Reversal Formed
Bullish Reversal
Momentum Back Above Zero-Line
As we've seen with our past winners, these low-float alerts have the tendency to bounce back hard, and can go viral at any moment.

The Company is trading well below its 52-week high of $4.00 giving it almost unlimited upside potential from today's alert price.

The Bottom Line

With its low-float, EVAHF is a day traders dream come true.

The Company appears to be in the midst of a major growth stage, and could rally hard from today's alert price.

We love their recent strategic acquisition, and believe it will serve as a major source of revenue in the very near future.

As we mentioned above, this could easily be our next trade idea to double in price, so we suggest you start your research now, and add it to the top of your watchlist immediately.By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Best regards,